Figure 4: Strong downregulation of Zfp423 correlates with poor prognosis.

(a) mRNA levels of the human orthologue of Zfp423, ZNF423, were measured in human glioma samples classified according to EGFR expression (GBM, GBM sample; HA, human astrocytes) by qRT–PCR. Data are represented as dCt (log₂ scale) relative to TBP; error bars represent the s.d. of technical replicates. (b) Kaplan–Meyer analysis of survival in low-grade glioma patients with high (red, n=17) or low (blue, n=11) ZNF423 expression levels (P<0.01, data obtained from The Cancer Genome Atlas, TCGA). (c) Survival and expression analysis of a large data set from the REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT). Left: Kaplan–Meyer analysis of survival in patients with high (red, n=77), intermediate (black, n=232) or low (blue, n=34) ZNF423 expression levels. Difference in progression-free survival between ZNF423 high- and low-expressing patients is statistically significant (P=1.65218e−5). Right: boxplots represent expression levels of ZNF423 in different samples grouped according to histopatological classification (P-values were computed with Mann–Whitney test). (d) Left: Kaplan–Meyer analysis of survival in mice injected with three representative AstroEGFR* cell lines (n=3 for AstroEGFR*1, n=4 for AstroEGFR*2 and n=3 for AstroEGFR*3). Right: Zfp423 mRNA levels in the same three AstroEGFR* cell lines (white bars) and in primary GPC derived from corresponding tumours (black bars). Data are represented as dCt (log₂ scale) relative to Tbp; error bars represent the s.d. of technical replicates.